Publication date: Jul 09, 2025
Today, well finalize a discussion about real-world data on adjuvant therapy in patients with BRAF-mutated melanoma. We discussed the visual comparison between immunotherapy and targeted therapy using real-world data. Targeted therapy has a different profile from immunotherapy, and this needs to be discussed with the patients, especially when we look into long-term toxicity. One is the number of patients, where more than 3600 patients were included. We didnt know if the patients were BRAF V600E or K, although the majority were reported as having BRAF V600E. The comparison was visually performed based on the formula that I mentioned in the first episode of this series. We have some advantages from this analysis. We also were not able to analyze the data based on the substage so stage IIIA to IIID. I look forward to your comments and to our next series together.
| Concepts | Keywords |
|---|---|
| Immunotherapies | Adjuvant |
| Monotherapy | Benefit |
| Stage | Braf |
| Teresa | Comparison |
| Data | |
| Free | |
| Included | |
| Pd | |
| Real | |
| Relapse | |
| Survival | |
| Targeted | |
| Therapies | |
| Therapy | |
| World |
Semantics
| Type | Source | Name |
|---|---|---|
| drug | DRUGBANK | Ipilimumab |
| drug | DRUGBANK | Tropicamide |
| disease | MESH | metastasis |
| disease | MESH | relapse |
| drug | DRUGBANK | Nonoxynol-9 |
| pathway | KEGG | Melanoma |
| disease | MESH | Melanoma |